BACKGROUND: Cavernous haemangiomas are rare benign bone tumours and those at the level of cranial bones are even rarer. The vertebral column is most often affected, followed by the skull. Calvarial cavernous haemangioma is rare, comprising about 0.2% of all benign neoplasms of the skull. CASE REPORT: We describe here, 2 patients with calvarial cavernous haemangioma that were localized frontally and parietally. The patients were of 45 years and 50 years of age, came with the history of dizziness and headache along with slow growing mass on frontal and parietal region respectively. The mass was soft to firm in consistency with freely mobile skin above the cavernoma sites. A computed tomography scan showed an osteolytic lesion with erosion of tabula externa. Total resection of the lesions and cranioplasty were performed in both the patients.Histopathology of the surgical sample revealed primary osseous cavernous type haemangioma showing large, thin walled, dilated capillary spaces lined by flattened endothelial cells without evidence of malignancy. CONCLUSION: Skull cavernous haemangioma are rare benign tumours. It should always be considered in the differential diagnosis of malignant skull lesions. Histopathological confirmation after surgical resection of tumour is the definitive method of diagnosis.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.